This week’s Medicare updates include the latest edition of the Medicare Quarterly Provider Compliance Newsletter, two new proposed decision memos on coverage for blood-based biomarker tests and a molecular expression test, updated information in the COVID-19 billing FAQs, and more!
The full U.S Court of Appeals declined to reconsider two recent decisions that upheld CMS’ cuts to reimbursement for certain off-campus provider-based department (PBD) visits and drugs acquired under the 340B program, the American Hospital Association (AHA) announced October 19.
Q: Starting January 1, 2021, CMS will be lowering reimbursement for high throughput novel coronavirus (COVID-19) diagnostic tests from $100 to $75. I understand that if certain requirements are met labs will be eligible to bill for a $25 add on code. How can we meet the requirements for the add on code?
This week’s Medicare updates include new payment incentives for COVID-19 testing, the addition of 11 services to the telehealth list, updated data on the impact of COVID-19 on Medicare beneficiaries, and more!
CMS will reduce payments to laboratories that take longer than two days to complete high-throughput COVID-19 diagnostic tests effective January 1, 2021, according to an October 15 press release.
CMS extended the timeline for organizations to repay payments received under its Accelerated and Advance Payment program, according to a fact sheet released October 8.
